Syndax shares rise as blood cancer therapy shows strong trial results
Syndax Pharmaceuticals (NASDAQ:SNDX) unveiled a broad array of clinical data reinforcing the therapeutic profile of its approved blood cancer drug, Revuforj, across several distinct mutations and stages of acute leukemia.
The Waltham, Massachusetts-based biotechnology firm highlighted the findings across 12 separate scientific abstracts at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden.
The pooled data sets tracked the clinical utility of Revuforj, scientifically known as revumenib, which functions as an oral, first-in-class small molecule inhibitor designed to block the menin-KMT2A protein interaction.
This specialized mechanism targets the underlying genetic drivers of both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) exhibiting specific chromosomal rearrangements or nucleophosmin 1 (NPM1) mutations.
The data drop underscored the drug’s performance when combined with traditional standards of care and intensive therapies.
In an updated frontline Phase 1 trial evaluating revumenib alongside intensive induction chemotherapy in 35 newly diagnosed patients with NPM1-mutated or KMT2A-rearranged AML, the treatment regimen yielded a 97% composite complete remission (CRc) rate.
Furthermore, 86% of those achieving a remission cleared all detectable genetic traces of the disease, achieving measurable residual disease (MRD) negativity.
In the real-world setting, interim findings from the observational ROAR study mirrored the drug's tightly controlled clinical trial performance.
Among 11 patients with relapsed or refractory disease treated with revumenib either as a standalone monotherapy or in varying clinical combinations, the drug achieved an 82% objective response rate (ORR) and a 64% complete remission rate.
The EHA presentations also shed light on the drug's long-term utility as a post-transplant maintenance therapy to stave off disease recurrence.
A post-hoc analysis extracted from the company's pivotal AUGMENT-101 trial evaluated 19 high-risk patients who resumed oral revumenib dosing following an allogeneic hematopoietic stem cell transplant.
The long-term monitoring revealed an observed 95% one-year overall survival (OS) rate, indicating that menin inhibition can safely prolong remission timelines without interfering with graft-versus-host dynamics.
